Cargando…

BRAF(V600E) Mutant Allele Frequency (MAF) Influences Melanoma Clinicopathologic Characteristics

SIMPLE SUMMARY: The mutational load of BRAF(V600E) in melanomas has been described as a possible prognostic biomarker but there is no information about the mutant allele frequency (MAF) variability of BRAF(V600E) within cutaneous melanomas and its potential prognostic implications. Our study suggest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soria, Xavier, Vilardell, Felip, Maiques, Óscar, Barceló, Carla, Sisó, Pol, de la Rosa, Inés, Velasco, Ana, Cuevas, Dolors, Santacana, Maria, Gatius, Sònia, Matías-Guiu, Xavier, Rodrigo, Alberto, Macià, Anna, Martí, Rosa M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533792/ https://www.ncbi.nlm.nih.gov/pubmed/34680222 http://dx.doi.org/10.3390/cancers13205073

Ejemplares similares

Differential Immunoexpression of BRAF/V600E, Senescence Markers, PTEN, and T-type Calcium Channels in Acquired Naevi According to their Histopathological and Dermoscopic Classification
por: MORENO, Sara, et al.
Publicado: (2021)

T-Type Calcium Channels: A Potential Novel Target in Melanoma
por: Barceló, Carla, et al.
Publicado: (2020)

Acral reed nevus with parallel ridge pattern: an exception to the rule of malignancy()
por: Canal-Garcia, Elena, et al.
Publicado: (2023)

FISH analysis of PTEN in endometrial carcinoma. comparison with SNP arrays and MLPA
por: Maiques, Oscar, et al.
Publicado: (2014)

Importance of assessing CK19 immunostaining in core biopsies in patients subjected to sentinel node study by OSNA
por: Vilardell, Felip, et al.
Publicado: (2012)

In vitro Cell Migration, Invasion, and Adhesion Assays: From Cell Imaging to Data Analysis
por: Pijuan, Jordi, et al.
Publicado: (2019)

An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias
por: Mirantes, Cristina, et al.
Publicado: (2013)

ARID1A‐deficient cells require HDAC6 for progression of endometrial carcinoma
por: Megino‐Luque, Cristina, et al.
Publicado: (2022)

Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer
por: Fusté, Noel P., et al.
Publicado: (2016)

Metabotyping human endometrioid endometrial adenocarcinoma reveals an implication of endocannabinoid metabolism
por: Jové, Mariona, et al.
Publicado: (2016)

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors
por: Choi, Sun Yi, et al.
Publicado: (2013)

Clinicopathological Significance of BRAF(V600E) Mutation in Colorectal Cancer: An Updated Meta-Analysis
por: Wang, Jianhua, et al.
Publicado: (2019)

Association between BRAF(V600E) mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma
por: Lu, Hai-Zhen, et al.
Publicado: (2017)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Protocol to characterize the melanoma tumor immune microenvironment in mice from single cell to flow cytometry analysis
por: Sisó, Pol, et al.
Publicado: (2023)

Clinicopathological features and BRAF(V600E) mutations in patients with isolated hypothalamic-pituitary Langerhans cell histiocytosis
por: Huo, Zhen, et al.
Publicado: (2016)

Association between clinicopathologic characteristics and BRAF(V600E) expression in Chinese patients with Langerhans cell histiocytosis
por: Huang, Hui, et al.
Publicado: (2019)

Melanotic Neuroectodermal Tumor of Infancy: A Clinicopathological and BRAF V600E Mutation Study of 11 Cases
por: Xia, Rong-Hui, et al.
Publicado: (2021)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

High Preponderance of BRAF V600E Mutation in Papillary Thyroid Carcinoma Among Filipinos: A Clinicopathologic Study
por: Espiritu, Gerard Anthony M., et al.
Publicado: (2019)

Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma
por: Zablocka, Tatjana, et al.
Publicado: (2022)

Early differential responses elicited by BRAF(V600E) in adult mouse models
por: Bosso, Giuseppe, et al.
Publicado: (2022)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

TGF-β-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination
por: Cantelli, Gaia, et al.
Publicado: (2015)

BRAF(V600E) mutation, BRAF-activated long non-coding RNA and miR-9 expression in papillary thyroid carcinoma, and their association with clinicopathological features
por: Shi, Chenlei, et al.
Publicado: (2020)

Characterization of the Maf family of polymorphic toxins in pathogenic Neisseria species
por: Jamet, Anne, et al.
Publicado: (2015)

Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer
por: Eritja, Núria, et al.
Publicado: (2017)

BRAF(V600E) Mutation and Its Association with Clinicopathological Features of Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Chen, Dong, et al.
Publicado: (2014)

The Association of BRAF V600E Mutation With Tissue Inhibitor of Metalloproteinase-3 Expression and Clinicopathological Features in Papillary Thyroid Cancer
por: Zarkesh, Maryam, et al.
Publicado: (2018)

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China
por: Huang, Meiling, et al.
Publicado: (2019)

Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer
por: Gatius, Sònia, et al.
Publicado: (2022)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

Sprouty1 is a candidate tumor suppressor gene in medullary thyroid carcinoma
por: Macià, Anna, et al.
Publicado: (2011)

Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain()()
por: Lopez-Martin, Jose A., et al.
Publicado: (2020)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Associations of the BRAF(V600E) Mutation with Sonographic Features and Clinicopathologic Characteristics in a Large Population with Conventional Papillary Thyroid Carcinoma
por: Park, Ah Young, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o12dlqi1lqc1dfpsk3umgnlkeo